Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019004464) ANTI-TUMOR IMMUNOTHERAPY ENHANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/004464 International Application No.: PCT/JP2018/024950
Publication Date: 03.01.2019 International Filing Date: 29.06.2018
IPC:
A61K 45/00 (2006.01) ,A61K 31/4365 (2006.01) ,A61K 31/4709 (2006.01) ,A61K 31/496 (2006.01) ,A61K 31/5025 (2006.01) ,A61K 31/506 (2006.01) ,A61K 31/517 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01) ,A61P 43/00 (2006.01) ,C07K 16/40 (2006.01) ,C12Q 1/26 (2006.01) ,G01N 33/15 (2006.01) ,G01N 33/50 (2006.01) ,G01N 33/68 (2006.01) ,C07D 215/54 (2006.01) ,C07D 401/14 (2006.01) ,C07D 405/14 (2006.01) ,C07D 417/12 (2006.01) ,C07D 487/04 (2006.01) ,C07D 495/04 (2006.01) ,C12N 15/53 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
4365
the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4709
Non-condensed quinolines containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50
Pyridazines; Hydrogenated pyridazines
5025
ortho- or peri-condensed with heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40
against enzymes
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
26
involving oxidoreductase
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
15
Medicinal preparations
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
215
Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
02
having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
16
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
48
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
54
attached in position 3
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
495
Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
52
Genes encoding for enzymes or proenzymes
53
Oxidoreductases (1)
Applicants:
学校法人慶應義塾 KEIO UNIVERSITY [JP/JP]; 東京都港区三田2丁目15番45号 15-45, Mita 2-chome, Minato-ku, Tokyo 1088345, JP
Inventors:
塚本 信夫 TSUKAMOTO Nobuo; JP
河上 裕 KAWAKAMI Yutaka; JP
Agent:
田中 伸一郎 TANAKA Shinichiro; JP
弟子丸 健 DESHIMARU Takeshi; JP
▲吉▼田 和彦 YOSHIDA Kazuhiko; JP
箱田 篤 HAKODA Atsushi; JP
浅井 賢治 ASAI Kenji; JP
山崎 一夫 YAMASAKI Kazuo; JP
市川 さつき ICHIKAWA Satsuki; JP
服部 博信 HATTORI Hironobu; JP
Priority Data:
2017-12797329.06.2017JP
Title (EN) ANTI-TUMOR IMMUNOTHERAPY ENHANCER
(FR) AGENT AMÉLIORANT L'IMMUNOTHÉRAPIE ANTITUMORALE
(JA) 抗腫瘍免疫療法増強剤
Abstract:
(EN) The purpose of the present invention is to provide a composition for inhibiting the proliferation and/or infiltration of tumor cells, an enhancer of an anti-tumor effect of a drug for the purpose of removing immunosuppression associated with cancer, or the like, which is characterized by being used for a specific subject. The present invention relates to a composition for inhibiting the proliferation and/or the infiltration of tumor cells, or an enhancer of an anti-tumor effect of a drug for the purpose of removing immunosuppression associated with cancer, wherein the composition or the enhancer contains a phosphorylation inhibitor or a dephosphorylation agent for the phosphorylation of a tyrosine residue located at position-111 and/or position-249 in human IDO1 or a position in non-human IDO1 which corresponds to position-111 and/or position-249 in human IDO1, and the composition or the enhancer can be used against tumor cells in which the tyrosine residue is phosphorylated and/or can be used in a subject who carries the tumor cells.
(FR) Le but de la présente invention est d’obtenir une composition permettant d’inhiber la prolifération et/ou l'infiltration de cellules tumorales, ainsi qu’un agent améliorant l’effet antitumoral d'un médicament dans le but d'éliminer une immunosuppression associée au cancer, ou similaire, qui sont caractérisés en ce qu'ils sont utilisés chez un sujet spécifique. La présente invention concerne une composition destinée à inhiber la prolifération et/ou l'infiltration de cellules tumorales, ou un agent améliorant l’effet antitumoral d'un médicament dans le but d'éliminer une immunosuppression associée au cancer, la composition ou l'agent contenant un inhibiteur de phosphorylation ou un agent de déphosphorylation pour la phosphorylation d'un résidu tyrosine situé en position 111 et/ou en position 249 dans l'IDO1 humain ou en une position dans l’IDO1 non humain qui correspond à la position 111 et/ou à la position 249 dans l'IDO1 humain, et la composition ou l'agent pouvant être utilisés contre des cellules tumorales dans lesquelles le résidu tyrosine est phosphorylé et/ou pouvant être utilisés chez un sujet portant les cellules tumorales.
(JA) 特定の対象に対して用いられることを特徴とする、腫瘍細胞の増殖及び/又は浸潤阻害用組成物、又はがんによる免疫抑制を解除するための薬剤の抗腫瘍作用増強剤等を提供することを目的とする。本発明は、ヒトIDO1の111位及び/又は249位、又は非ヒトIDO1におけるヒトIDO1の111位及び/又は249位に対応する位置のチロシンのリン酸化に対するリン酸化阻害剤又は脱リン酸化剤を含む、前記チロシンがリン酸化された腫瘍細胞に対して使用する又は前記腫瘍細胞を有する被験者に使用するための、前記腫瘍細胞の増殖及び/又は浸潤阻害用組成物、又はがんによる免疫抑制を解除するための薬剤の抗腫瘍作用増強剤に関する。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)